About this file

This is a Small Business Innovation Research (SBIR) solicitation topic for host-directed therapeutics development targeting viral diseases. The topic, CBD244-P001, falls under the Chemical and Biological Defense technology area with biotechnology as the modernization priority. No CMMC level requirement or technical point of contact has been designated. The solicitation is designated as an open topic without set-asides.

The objective is to develop and demonstrate efficacy of broadly active host-directed therapeutics (HDTs) for treatment or prophylactic medical countermeasures against viral infections, specifically targeting Filoviruses, Togaviruses (Alphaviruses), Arenaviruses, Paramyxoviruses, Poxviruses (Orthopoxviruses), and Hantaviruses. Phase I requires identification and development of viral strains or surrogate assays for screening, followed by identification of inhibitors to virus replication with assessment of in vitro antiviral activity, host response parameters, and cytotoxicity. Phase II involves optimization of the lead compound through medicinal chemistry, formulation, or bioengineering approaches to enhance in vitro activity, supplemented by preclinical efficacy studies and development of working viral stocks within high containment laboratories. Phase III encompasses preclinical development of down-selected candidates to support an Investigational New Drug (IND) application submission, construction of a development plan in consultation with a sponsor and the FDA, identification of appropriate animal models, development of Good Manufacturing Practices (GMPs), and conduct of safety trials. The solicitation emphasizes dual-use applications, noting that therapeutics developed will benefit both civilian and military populations at risk from these viral agents.

View the file

Other files

File Type Posted
CBD_SBIR_244_R1.pdf PDF

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

CBD244-P001: Host Directed Therapeutics for treatment for viral disease – Open Topic

PROJECTED CMMC LEVEL REQUIREMENT:

N/A

TECHNOLOGY AREAS:

Chem Bio Defense

MODERNIZATION PRIORITIES:

Biotechnology

KEYWORDS:

host-directed, antiviral, small molecule, biopharmaceutical, Bunyavirus, Arenavirus, Viral Hemorrhagic Fever, Alphavirus, Ebolavirus, Filovirus, Paramyxovirus

ADDITIONAL INFORMATION

N/A

OBJECTIVE:

The goal of this SBIR is to develop and demonstrate efficacy of broadly active host directed therapeutics to be used as treatment, either as sole agents or as combination agents, in the event of disease or as prophylactic medical countermeasures (MCM) following human exposure or threat of exposure to viral infections of interest.

DESCRIPTION:

Host-directed Therapeutics (HDTs) are therapies that target either human host factors or pathways that are necessary for a virus to replicate/propagate, or the host responses to infection that lead to disease symptoms.

HDTs increase or decrease the production of host factors that affect viral replication and propagation, and other target host antiviral responses. In contrast, direct-acting antiviral (DAAs) therapeutics directly target the function of viral proteins. Unlike DAAs, HDTs are generally expected to be effective against drug resistant mutants and some HDTs would provide a higher barrier to resistance. HDTs are expected to be effective against multiple serotypes (e.g., Dengue), clades (HIV) or genotypes (HCV). HDTs can potentially be broad acting (activity against several families) counter measures that can be used either as a PEP or treatment in conjunction of DAAs. Disease signs (measurable medical responses to infection) and symptoms (infection responses felt by the patient such as headache) including hemorrhagic fevers, encephalitis, musculoskeletal disease, acute respiratory distress syndrome, and paralysis are largely dependent upon the viral pathogen’s mechanism of pathogenesis, including cell tropism, pathogen mechanism of immune evasion, and specific-host pathogen interactions (intra- and extracellular).

Viral biothreat families of interest to the DOD include: Filoviruses, Togaviruses (Alphaviruses), Arenaviruses, Paramyxoviruses, Poxviruses (Orthopoxviruses), and Hantaviruses. Currently, there are some approved directly acting antivirals for some of these pathogens (ex. TPOXXTM for smallpox treatment, InmazebTM and EbangaTM for Ebola Zaire treatment), however, there are gaps in treatment options for these serious viral infections. This topic solicitation focuses on funding innovative host-directed therapeutic solutions for treatment of infections caused by one or more of these viral families.

PHASE I:

The objective of this Phase is to identify broadly-acting host-directed therapeutics against infection by viruses of interest. This Phase will be accomplished by: A) Identification and development of working stocks of appropriate strains of virus(es) for testing. Alternatively, surrogate assays (e.g. pseudotyped particles, replicase assays) in lower safety containment laboratories are sufficient for early screening. B) Identify inhibitors to virus replication of one or more of the members of the virus families discussed previously. Modeling data for broad-spectrum inhibition of replication can be used to begin intermediate development at the Phase II stage. The screening should assess in vitro antiviral activity, in vitro parameters of host response, and cytotoxicity.

PHASE II:

The objective of this phase is to optimize the lead compound identified in Phase 1 through medicinal chemistry, formulation or bioengineering approaches to enhance in vitro activity against viral infections of interest . Further assessment of antiviral activity will be provided through preclinical efficacy studies. This stage will require development of working stocks of appropriate strains of virus(es) for testing if not developed in Phase I and performance within high containment laboratories.

PHASE III DUAL USE APPLICATIONS:

PHASE III: Preclinical development of down-selected candidates to support submission of an application for an IND. Construction of a Development Plan through consultation with a sponsor and the U.S. Food and Drug Administration (FDA). Discussions and preparations would include identification of appropriate lead therapeutic(s), animal models, additional animal model studies, development of Good Manufacturing Practices (GMPs) and the conduct of safety trials.

PHASE III DUAL USE APPLICATIONS: Some of the agents listed here lack treatment options, and any therapeutic derived from this research will be of significant use for both civilian and military populations at risk.

REFERENCES:

Kumar N, Sharma S, Kumar R, Tripathi BN, Barua S, Ly H, Rouse BT. 2020. Host-directed antiviral therapy.

Clin Microbiol Rev 33:e00168-19. https://doi.org/10.1128/CMR.00168-19.

1.

Meyer B, Ly H. Inhibition of Innate Immune Responses Is Key to Pathogenesis by Arenaviruses. J Virol. 2016, 90(8):3810-3818. Published 2016 Mar 28. doi:10.1128/JVI.03049-15

2.

Mackow ER, Gavrilovskaya IN. Hantavirus regulation of endothelial cell functions. Thromb Haemost. 2009 Dec, 102(6):1030-41. doi: 10.1160/TH09-09-0640. PMID: 19967132.

3.

Gardner CL, Burke CW, Tesfay MZ, Glass PJ, Klimstra WB, Ryman KD. Eastern and Venezuelan equine encephalitis viruses differ in their ability to infect dendritic cells and macrophages: impact of altered cell tropism on pathogenesis. J Virol. 2008, 82(21):10634-10646. doi:10.1128/JVI.01323-08

4.

Https://www.fda.gov/drugs/emergency-preparedness-drugs/emergency-use-authorizations-drugs-and-non-vaccine-biological-products, accessed May 17, 2023

5.

Fullen DJ, Noulin N, Catchpole A, Fathi H, Murray EJ, Mann A, et al. (2016) Accelerating Influenza Research:

Vaccines, Antivirals,Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model. PLoS ONE 11(1):e0145902.

doi:10.1371/journal.pone.0145902

6.

https://www.appliedclinicaltrialsonline.com/view/human-challenge-studies-early-phase-antiviral-development, accessed May 17, 2023

7.

Adams-Phipps J, Toomey D, Więcek W, Schmit V, Wilkinson J, Scholl K, Jamrozik E, Osowicki J, Roestenberg M, Manheim D. A Systematic Review of Human Challenge Trials, Designs, and Safety. Clin Infect Dis. 2023 Feb 18, 76(4):609-619. doi: 10.1093/cid/ciac820. PMID: 36219704, PMCID: PMC9938741.

8.

Tripathi D, Sodani M, Gupta P, Kulkarni, S. 2021 Host directed therapies: COVID-19 and beyond. Current Research in Pharmacology and Drug Discovery 2 (2021) 100058 https://doi.org/10.1016/j.crphar.2021.100058

9.

Stefan H. E. Kaufmann1, Anca Dorhoi1,2, Richard S. Hotchkiss3 and Ralf Bartenschlager4,5, Host-directed therapies for bacterial and viral infections JANUARY 2018 | VOLUME 17

10.

Alimuddin Zumla, Martin Rao, Robert S Wallis, Stefan H E Kaufmann, Roxana Rustomjee, Peter Mwaba, Cris Vilaplana, Dorothy Yeboah-Manu, Jeremiah Chakaya, Giuseppe Ippolito, Esam Azhar, Michael Hoelscher, Markus Maeurer, for the Host-Directed Therapies Network consortium* Host directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect Dis 2016, 16: e47–63

11.

TECHNICAL POINT OF CONTACT (TPOC):

None

File details come from the government source that posted it. Updated .